Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329314 | 0.98 | KCNH2 (0.48) | KCNH2RAB9ADUSP3PTPN11KMT2A | |
| SCHEMBL1544442 | 0.85 | KCNH2 (0.47) | KCNH2RAB9ASMN1; SMN2BCHECYP3A4 | |
| SCHEMBL1543916 | 0.85 | KCNH2 (0.46) | KCNH2KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL4327916 | 0.83 | KCNH2 (0.47) | KCNH2RAB9ASMN1; SMN2BCHECYP3A4 | |
| SCHEMBL1545201 | 0.80 | KCNH2 (0.43) | KCNH2RAB9ADUSP3PTPN11KMT2A | |
| SCHEMBL5482293 | 0.76 | P2RX7 (0.40) | KCNH2RAB9ASMN1; SMN2NPC1PKM | |
| SCHEMBL1544389 | 0.75 | CHRNB2 (0.44) | RAB9ACYP3A4NPC1ADORA2APSEN1 | |
| SCHEMBL5478892 | 0.75 | MAPT (0.40) | KCNH2RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4336808 | 0.75 | MAPT (0.38) | KCNH2RAB9ASMN1; SMN2NPC1PKM | |
| SCHEMBL4708679 | 0.74 | KCNH2 (0.47) | KCNH2RAB9ASMN1; SMN2BCHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716152-B1 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | claimed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| EP-1716152-A2 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | claimed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-12 | — | — | US | claimed |
| WO-2005080397-A2 | FUSED HETROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | claimed |
| WO-2005077345-A1 | COMPOUNDS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE | ASTRAZENECA AB (SE) | 2005-08-25 | — | — | WO | claimed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | claimed |
| EP-1301519-B2 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES INC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3235823-A1 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | Gilead Sciences, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2682397-B1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-1301519-B1 | PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2682397-A1 | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same | GILEAD SCIENCES, INC. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2005077345-A1 | COMPOUNDS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE | ASTRAZENECA AB (SE) | 2005-08-25 | — | — | WO | disclosed |
| US-20050124585-A1 | Prodrugs of phosphonate nucleotide analogues | BECKER MARK W (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM5 | KCNH2 672/4885RAB9A 929/4885DUSP3 4581/4885 |
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | KCNH2 1764/4885RAB9A 1283/4885DUSP3 4400/4885 |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | KCNH2 710/4885RAB9A 1153/4885DUSP3 3512/4885 |
| US-20060009443-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM5 | KCNH2 513/4885RAB9A 1393/4885DUSP3 4532/4885 |
| US-20050124585-A1 | Prodrugs of phosphonate nucleotide analogues | PNP, TYMP, APRT | KCNH2 4661/4885RAB9A 2115/4885DUSP3 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.